Drug Trial Radar · NCT01757184
Acid Lipase Replacement Investigating Safety and Efficacy (ARISE) in Participants With Lysosomal Acid Lipase Deficiency
Last checked: Nov 20, 2026Latest source record: Dec 29, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
66
Actual
Start
Jan 22, 2013
Primary completion
May 30, 2014
Study completion Dec 11, 2018
Sponsor
- Lead sponsor
- Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Dec 28, 2012
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 4 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase 3 study evaluated the efficacy and safety of 1 milligram/kilogram (mg/kg) intravenous (IV) infusions of SBC-102 (sebelipase alfa) administered every other week (qow) in participants with late onset lysosomal acid lipase deficiency (LAL-D) (cholesteryl ester storage disease \[CESD\]). Late-onset LAL-D is an underappreciated cause of cirrhosis, liver failure and dyslipidemia. There is currently no standard treatment for LAL-D other than supportive care. Enzyme replacement therapy may be a potential new treatment option for LAL-D participants.
Conditions
- Lysosomal Acid Lipase Deficiency
Interventions
Sebelipase AlfaDrug
IV infusions of sebelipase alfa
PlaceboDrug
IV infusions of matched placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage Of Participants Achieving Alanine Aminotransferase NormalizationTime frame: Double-blind Period: Baseline to the end of the Double-blind Period (Week 20). Open-label Period: Baseline to the last Open-label assessment (up to Week 256)
Locations
40 sites in 15 countries. Site status is shown where the registry gives one.
Site not named
Tucson, Arizona
Site not named
Palo Alto, California
Site not named
San Francisco, California
Site not named
Wilmington, Delaware
Site not named
Chicago, Illinois
Site not named
Boston, Massachusetts
Site not named
Buffalo, New York
Site not named
Manhasset, New York
Site not named
New York, New York
Site not named
Cincinnati, Ohio
Site not named
Philadelphia, Pennsylvania
Site not named
Córdoba, Argentina
Site not named
Brisbane, Australia
Site not named
New Lambton, Australia
Site not named
Parkville, Australia
Site not named
Perth, Australia
Site not named
Zagreb, Croatia
Site not named
Olomouc, Czechia
Site not named
Prague, Czechia
Site not named
Paris, France
Site not named
Vandœuvre-lès-Nancy, France
Site not named
Freiburg im Breisgau, Germany
Site not named
Mainz, Germany
Site not named
Munich, Germany
Site not named
Bergamo, Italy
Site not named
Genoa, Italy
Site not named
Padova, Italy
Site not named
Tokyo, Japan
Site not named
Tottori, Japan
Site not named
Mexico City, Mexico
Site not named
Warsaw, Poland
Site not named
Moscow, Russia
Site not named
Elche, Spain
Site not named
Madrid, Spain
Site not named
Oviedo, Spain
Site not named
Ankara, Turkey (Türkiye)
Site not named
Izmir, Turkey (Türkiye)
Site not named
Cambridge, United Kingdom
Site not named
London, United Kingdom
Site not named
Plymouth, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.